Effectiveness of preemptive antifibrinolysis with tranexamic acid in rheumatoid arthritis patients undergoing total knee arthroplasty: a study protocol for a randomized controlled trial.

Abstract

BACKGROUND:

Patients with rheumatoid arthritis (RA) who have undergone total knee arthroplasty are at increased risk of requiring a blood transfusion. This study is designed to compare the effects of preemptive antifibrinolysis of single-dose and repeat-dose tranexamic acid (TXA) in in RA patients undergoing total knee arthroplasty (TKA).

METHODS/DESIGN:

The study will be a double-blind randomized controlled trial with two parallel groups of RA patients. Group A will be given 100 ml normal saline twice daily starting from 3 days before the operation, Group B will be given TXA 1.5 g twice daily starting from 3 days before the operation. All patients will be given TXA 1.5 g 30 min before the operation. The primary outcomes will be evaluated with total blood loss and hidden blood loss. Other outcome measurements such as, fibrinolysis parameters, inflammatory factors, visual analogue scale for post-operative pain, analgesia usage, coagulation parameters, transfusion, the length of stay (LOS), total hospitalization costs, the incidence of thromboembolic events and other complications will be recorded and compared. Recruitment is scheduled to begin on 1 August 2020, and the study will continue until 31 May 2021.

DISCUSSION:

In current literature there is a lack of evidence with regard to the efficacy of TXA in RA patients. The findings of this study, whether positive or negative, will contribute to the formulation of further recommendations on the use of TXA in RA patients undergoing TKA.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry, ChiCTR2000029720 . Registered 14 February 2020.

• Authors: Yiting Lei, Jiacheng Liu, Xi Liang, Ning Hu, Fuxing Pei, Wei Huang
• Journal: BMC musculoskeletal disorders (BMC Musculoskelet Disord) Vol. 21 Issue 1 Pg. 465 (Jul 15 2020) ISSN: 1471-2474 [Electronic] England
• PMID: 32669099 (Publication Type: Clinical Trial Protocol, Journal Article)

Chemical References

• Antifibrinolytic Agents
• Tranexamic Acid

Topics

• Administration, Intravenous
• Antifibrinolytic Agents (adverse effects)
• Arthritis, Rheumatoid (complications, diagnosis, drug therapy)
• Arthroplasty, Replacement, Knee (adverse effects)
• Blood Loss, Surgical (prevention & control)
• Humans
• Postoperative Hemorrhage (chemically induced, epidemiology)
• Randomized Controlled Trials as Topic
• Tranexamic Acid (adverse effects)